GlaxoSmithKline CEO: More Transparency Is Needed in Drug Pricing
1,239 views · Published 4 November 2015 · 10:20 · Indexed 2 October 2026
Channel: Bloomberg Originals · 2015 · News & Politics
Nov. 3 -- Andrew Witty, GlaxoSmithKline's chief executive officer, discusses the company's growth prospects, the Pfizer-Allergan talks and drug pricing. He speaks with Bloomberg's Erik Schatzker and Cynthia Koons on "What'd You Miss?"
More from this channel
-
3:30
Market Close 6.4 - Bloomberg
-
0:17
Pens Tie Stanley Cup Series - Bloomberg
-
0:35
Hardware Price Too High - Activision - Bloomberg
-
0:31
FDIC Seeks Citigroup Shares-Up - WSJ - Bloomberg
-
0:44
Bank Have More Accounting Leeway - Bloomberg
-
0:32
Lakers Beat Magic 100-75 - Bloomberg
-
0:30
Johnson Wins 300th Game - Bloomberg
-
1:13
GM Expects To Sell Saturn To Penske Automotive - Bloomberg